Listen to The Lancet Oncology

Eric Deutsch (Gustave Roussy Comprehensive Cancer Center, Villejuif, France) presents The Lancet Oncology ’s latest series on advances in radioimmunotherapy for cancer.

Georgina Long (The University of Sydney, Sydney, NSW, Australia) discusses three papers from The Lancet Oncology on neoadjuvant approaches for melanoma treatment.

Jens Hillengass discusses the new International Myeloma Working Group consensus guidelines on optimal use of imaging methods for monoclonal plasma cell disorders.

Kee Yuan Ngiam (National University Hospital Singapore, Singapore) discusses a duo of papers exploring big data and machine-learning algorithms for healthcare delivery and pathology in oncology.

CS Pramesh discusses ten low-value or harmful practises that should be avoided in cancer care in India.

Bianca Hoeben discusses the latest guidelines from the SIOPE radiotherapy working group on vertebral radiotherapy dose in paediatric patients.

Anna Bibby joins  The Lancet Oncology to discuss recent developments in the treament of malignant plural mesothelioma.

Frederick Locke joins  The Lancet Oncology to discuss long-term results from the ZUMA-1 trial on the safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma.

Talía Malagón discusses her modelling study which assesses the age at which to stop cervical cancer screening in older women and the remaining lifetime risk of cervical cancer.

Stein Kaasa and Jon Loge discuss their new Commission on palliative care.

Andre Ilbawi talks about his global analysis of available national cancer control plans with  The Lancet Oncology.

A review in  The Lancet Oncology asks whether patient reported outcomes in RCTs are consistent across their analysis, reporting, and interpretation. Author Madeline Pe discusses the findings.

Eva Steliarova-Foucher joins  The Lancet Oncology to discuss the Europe-wide Automated Childhood Cancer Information System, and the increase in cancer incidence rates among children and adolescents.

Mark Souweidane joins The Lancet Oncology  to discuss his dose-escalation study, assessing a convection-enhanced delivery for diffuse intrinsic pontine glioma.

Bo Jan Noordman joins The Lancet Oncology to discuss the findings from his study of residual disease detection in oesophageal cancer.

Fabio Conforti talks to The Lancet Oncology about a meta-analysis showing that a patient's sex can affect the efficacy of cancer immunotherapy.

Paul Kluetz from the US FDA discusses the issues surrounding the use of patient-reported outcomes in regulatory decision making.

Michael Hoeckel joins  The Lancet Oncology to discuss his latest trial on the surgical treatment of vulvar carcinoma based on the theory of ontogenetic cancer fields.

Håvard Emil Danielsen joins  The Lancet Oncology to discuss his latest paper on machine learning algorithms to analyse chromatin organisation as a prognostic marker for cancer.

Ross Camidge discusses RANO's papers on clinical trial design for patients with brain metastases.

John Field discusses a European position statement on lung cancer screening using low-dose CT.

Commission co-chairs Chi Van Dang and Elizabeth M. Jaffee discuss a new Lancet Oncology Commission on cancer treatment and care in the USA.

Ben Anderson talks about cancer care and cancer trends in Peru.

Ricky Sharma discusses results from three prospective trials on the use of selective internal radiotherapy for liver metastases from colorectal cancer.

Samra Turajlic discusses the contribution of small insertions and deletions to tumour-specific antigen analyses.